Integra LifeSciences Holdings Corporation (IART) Guidance & Earnings Results

On 2026-10-21 Integra LifeSciences Holdings Corporation reaffirmed guidance: "FY2026 revenue $1.634-1.654B; FY2026 adjusted EPS…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-09-30 · read by EquiReason

IARTIntegra LifeSciences Holdings CorporationFollow IART — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 926.6M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 24 Feb, in 123 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
21 Oct 26	Reaffirmed	FY2026 revenue $1.634-1.654B; FY2026 adjusted EPS $2.30-2.40 · full year
2 Oct 26	Lowered	FY2026 revenue and adjusted EPS lowered; Q3 revenue $410-412M, adj. EPS $0.55-0.59, operating cash flow >$85M; FY operating cash flow ~$190-200M · full year
29 Jul 26	Mixed	FY26 reported revenue updated to $1.654B-$1.695B from $1.662B-$1.702B; FY26 organic revenue growth reaffirmed 0.8%-3.3%; FY26 adjusted EPS reaffirmed $2.40-$2.50; Q3 2026 reported revenue $410M-$425M; Q3 2026 adjusted EPS $0.53-$0.61 · full year
30 Oct 25	Lowered	Full year 2025 revenue guidance lowered to $1.620B-$1.640B (organic -1.6% to -0.4%); Q4 revenue $420M-$440M (organic -5.9% to -1.4%); adjusted EPS $2.19-$2.24 · full year
31 Jul 25	Reaffirmed	Q3 2025 revenue $410M-$420M (reported growth 7.7%-10.3%, organic 7.3%-9.9%); Q3 2025 adjusted EPS $0.40-$0.45

Integra LifeSciences Holdings Corporation — questions

What guidance did Integra LifeSciences Holdings Corporation give?: On 2026-10-21: "FY2026 revenue $1.634-1.654B; FY2026 adjusted EPS $2.30-2.40"
When does Integra LifeSciences Holdings Corporation report earnings?: Integra LifeSciences Holdings Corporation's next earnings report is expected on 2027-02-24.

Every figure on this page comes from Integra LifeSciences Holdings Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.